Updated efficacy and safety data from a phase II, single-arm, open-label study of durvalumab plus gemcitabine, cisplatin, and nab-paclitaxel (DurGAP) in resectable biliary tract cancer
Background: Our previous research (2024 ASCO Abstract: e16260) highlighted the efficacy and safety data of DurGAP in resectable biliary tract cancer (BTC). This study aims to provide an updated analysis of the safety and efficacy of neoadjuvant DurGAP for resectable BTC in our latest cohort of 30 pa...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-02-01
|
| Series: | The Lancet Regional Health. Western Pacific |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S266660652400347X |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|